Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: Incidence and implications for hematologic recovery and clinical outcome

Bone Marrow Transplantation

Volumn 20, Issue 10, 1997, Pages 813-819

  Beyer, J ^a   Rick, O ^a   Weinknecht, S ^b   Kingreen, D ^a   Lenz, K ^a   Siegert, W ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b VIVANTES KLINIKUM AM URBAN   (Germany)

Author keywords

Antineoplastic agents therapeutic use; Antineoplastic agents toxicity; Bone marrow transplantation; Hematopoietic stem cell transplantation; Prognosis; Testicular neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; GERM CELL TUMOR; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030783771     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700980     Document Type: Article

References (17)

1. Wilson WH, Jain V, Bryant G et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 1992; 10: 1712-1722.
2. Elias AD, Ayash LJ, Wheeler C et al. Phase I study of high-dose ifosfamide, carboplatin, and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15: 373-379.
3. Lotz JP, Andre T, Donsimoni R et al. High-dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995; 75: 874-885.
4. Fields K, Elfenbein GJ, Lazarus H et al. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995; 13: 323-332.
5. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12: 1223-1231.
6. Beyer J, Kingreen D, Krause M et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high-dose chemotherapy. Cancer 1997; 79: 161-168.
7. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
8. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. New Engl J Med 1996; 334: 1448-1460.
9. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Cox DR. Regression models and life-tables. JR Stat Soc (B) 1972; 34: 187-220.
11. Barnett MJ, Coppin CML, Murray N et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumors. Br J Cancer 1993; 68: 594-598.
12. Broun ER, Nichols CR, Tricot G et al. High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant 1991; 7: 53-56.
13. Rosti G, Albertazzi L, Salvioni R et al. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol 1992; 3: 809-812.
14. Margolin K, Doroshow JH, Ahn C et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin and etoposide with autologous stem-cell support. J Clin Oncol 1996; 10: 2631-2637.
15. Goren MP, Wright RK, Pratt CB et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 1987; 47: 1457-1460.
16. Rossi R, Gödde A, Kleinebrand A et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12: 159-165.
17. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.